{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:14:14Z","timestamp":1786976054558,"version":"build-2736575974"},"reference-count":146,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000440","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:20:09Z","timestamp":1069366809000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Risperidone versus typical antipsychotic medication for schizophrenia"],"prefix":"10.1002","author":[{"given":"Robert","family":"Hunter","sequence":"first","affiliation":[{"name":"Greater Glasgow Primary Care NHS Trust; Research and Development; Gartnavel Royal Hospital 1055 Great Western Road Glasgow Scotland UK G12 0XH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilis","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Tavistock Clinic; Child and Family Department; 120 Belsize Lane Hampstead London UK NW3 5BA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujian","family":"Song","sequence":"additional","affiliation":[{"name":"University of East Anglia; School of Medicine, Health Policy and Practice; Norwich Norfolk UK NR4 7TJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gadon","sequence":"additional","affiliation":[{"name":"Glasgow Caledonian University; Glasgow Centre for the Study of Violence; Cowcaddens Road Glasgow UK G4 0BA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire B","family":"Irving","sequence":"additional","affiliation":[{"name":"The University of Nottingham; Cochrane Schizophrenia Group; Institute of Mental Health, Sir Colin Campbell Building University of Nottingham Innovation Park, Triumph Road Nottingham UK NG7 2TU"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,4,22]]},"reference":[{"key":"10.1002\/14651858.CD000440-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-199602000-00007","article-title":"Antipsychotic and anxiolytic properties of risperidone, haloperidol and methotrimeprazine in schizophrenic patients","volume":"16","author":"Blin","year":"1996","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0002|cit2","unstructured":"Tatossian A Comparitive double-blind trial of the efficacy of risperidone, haloperidol and levomepromazine (methotrimeprazine) in patients with an acute exacerbation of schizophhrenia presenting psychotic anxiety symptoms Clinical research report (RIS-FRA-9003) 1991(unpublished data from Janssen)"},{"key":"10.1002\/14651858.CD000440-BIB0004|cit3","unstructured":"Borison R Risperidone versus haloperidol versus placebo in the treatment of schizophrenia Clinical research report (RIS-USA-9001) 1991(unpublished data from Janssen)"},{"key":"10.1002\/14651858.CD000440-BIB0003|cit4","first-page":"213","article-title":"Risperidone: clinical safety and efficacy in schizophrenia","volume":"28","author":"Borison","year":"1992","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000440-BIB0005|cit5","unstructured":"Bouchard RH Demers MF Merette C Pourcher E Classical neuroleptics (CNLP) vs risperdone (RIS) interim 12 months efficacy of a long-term, naturalistic study in schizophrenics 11th CINP Congress, Glasgow, Scotland"},{"key":"10.1002\/14651858.CD000440-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2007-1014355","article-title":"Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses","volume":"26","author":"Ceskova","year":"1993","journal-title":"Pharmacopsychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000440-BIB0008|cit7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00004714-199502001-00007","article-title":"Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study","volume":"15","author":"Chouinard","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0007|cit8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF02191543","article-title":"A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a re-evaluation of the North American risperidone study","volume":"245","author":"Moller","year":"1995","journal-title":"European Achives of Pychiatry and Clinical Neurosciences"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD000440-BIB0010|cit10","first-page":"22","article-title":"Negative symptoms in schizophrenia: assesment of the effect of risperidone","volume":"55","author":"Schooler","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0447.1992.tb01473.x","article-title":"Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparitive study","volume":"85","author":"Claus","year":"1992","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000440-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1600-0447.1992.tb01474.x","article-title":"Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients","volume":"85","author":"Wilms","year":"1992","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000440-BIB0013|cit13","unstructured":"Csernansky J Okamoto A 11th World Congress of Psychiatry; 1999 August; Hamburg 1999"},{"issue":"1","key":"10.1002\/14651858.CD000440-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1056\/NEJMoa002028","article-title":"A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia","volume":"346","author":"Csernansky","year":"2002","journal-title":"The New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000440-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Csernansky JG Okamoto A Brecher M Risperidone vs haloperidol: prevention of relapse in schizophrenia Journal of the European College of Neuropsychopharmacology (Abstracts of the 12th ECNP Congress; 1999 September 21-25th; London,UK 1999","DOI":"10.1016\/S0924-977X(99)80288-0"},{"key":"10.1002\/14651858.CD000440-BIB0016|cit16","unstructured":"Harvey P Meltzer H Green M Long-term cognitive effects of risperidone treatment in schizophrenia Abstracts of the XXIInd CINP Congress; 2000 July 9-13th; Brussels, Belgium 2000"},{"key":"10.1002\/14651858.CD000440-BIB0018|cit17","unstructured":"Harvey PD Long-term cognitive effects of risperidone treatment in schizophrenia 52nd Institute on Psychiatric Services; 2000 October 25-29th; Phildelphia PA, USA 2000"},{"issue":"1","key":"10.1002\/14651858.CD000440-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0920-9964(00)90795-3","article-title":"Long term cognitive effects of risperidone","volume":"41","author":"Harvey","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0019|cit19","unstructured":"Myers J Mahmoud R Keith SJ Csernansky JG Abstracts of the VIII International Congress on Schizophrenia Research; 2001 April 28th -May 2nd; British Columbia, Canada 2001"},{"key":"10.1002\/14651858.CD000440-BIB0020|cit20","unstructured":"Emsley R McCreadie R Livingston M De Smedt G Lemmens P Risperidone in the treatment of first-episode schizophrenic patients with schizophreniform disorder: a double blind study Poster at the Congress of the International Academy for Biomedical and Drug Research on Critical Issues in the Treatment of Schizophrenia 1995 N 112027\/1"},{"key":"10.1002\/14651858.CD000440-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0920-9964(00)00009-8","article-title":"Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-centre trial","volume":"46","author":"Heck","year":"2000","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","article-title":"Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations","volume":"88","author":"Hoyberg","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000440-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0447.1995.tb09781.x","article-title":"Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel group trial","volume":"91","author":"Huttunen","year":"1995","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000440-BIB0024|cit24","unstructured":"Kaleda VG Oleichik IV Artiokh VV Naddour SA Abstracts of the XXIInd CINP Congress; 2000 July 9-13th; Brussels, Belgium 2000"},{"issue":"3","key":"10.1002\/14651858.CD000440-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0893-133X(99)00137-2","article-title":"Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol","volume":"22","author":"Liu","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0026|cit26","unstructured":"Mahmoud RA Engelhart LM Risperidone Outcome Study of Effectiveness (ROSE) Group Janssen Research Foundation Risperidone versus conventional antipsychotics in usual care: a prospective randomised effectiveness trial of outcomes for patients with schizophrenia and schizoaffective disorder 11th CINP Congress; Glasgow, Scotland,"},{"key":"10.1002\/14651858.CD000440-BIB0027|cit27","unstructured":"Merideth C Mahmoud RA Englehart LM Ramirez L the ROSE Group Clinical and quality of life superiority of risperidone over conventional antipsychotics under usual care conditions: a prospective randomised trial in schizophrenia and schizoaffective disorder 151st Annual Meeting of the American Psychiatric Association"},{"key":"10.1002\/14651858.CD000440-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Malyarov S Dzub G Comparative assessment of the positive and negative symptom dynamics in schizophrenic patients treated with atypical antipsychotics or haloperidol Abstracts of the 12th ENCP Congress;1999 September 21-25th; London, UK 1999","DOI":"10.1016\/S0924-977X(99)80369-1"},{"key":"10.1002\/14651858.CD000440-BIB0029|cit29","first-page":"614","article-title":"Schizophrenes negativsyndrom risperidone erfolgreich","volume":"11","author":"Blaeser-Kiel","year":"1994","journal-title":"Neurologie Psychiatrie"},{"key":"10.1002\/14651858.CD000440-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004714-199508000-00002","article-title":"Effect of risperidone on hostility in schizophrenia","volume":"15","author":"Czobor","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0920-9964(94)00041-6","article-title":"Five factor model of schizophrenia: replication across samples","volume":"14","author":"Lindenmayer","year":"1995","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"American Journal of Psychiatry"},{"issue":"suppl 5","key":"10.1002\/14651858.CD000440-BIB0033|cit33","first-page":"18","article-title":"Efficacy of risperidone on positive features of schizophrenia","volume":"55","author":"McEvoy","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"issue":"suppl 5","key":"10.1002\/14651858.CD000440-BIB0034|cit34","first-page":"22","article-title":"Negative symptoms in schizophrenia: assesment of the effect of risperidone","volume":"55","author":"Schooler","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0035|cit35","unstructured":"Messotten F Risperidone versus haloperidol in the teatment of chronic psychotic patients: a multicentre double-blind study Clinical research report (RIS-INT-2, N 85163) 1991(unpublished data from Janssen)"},{"key":"10.1002\/14651858.CD000440-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3349\/ymj.1993.34.2.179","article-title":"Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial","volume":"34","author":"Min","year":"1993","journal-title":"Yansei Medical Journal"},{"key":"10.1002\/14651858.CD000440-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-2007-1014288","article-title":"Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol","volume":"7","author":"Lindstrom","year":"1994","journal-title":"Pharmacopsychiatry"},{"issue":"suppl 1","key":"10.1002\/14651858.CD000440-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"90A","DOI":"10.1097\/00002826-199201001-00048","article-title":"Risperidone in the treatment of chronic schizophrenic patients: an inernational double-blind parallel group study versus haloperidol","volume":"15","author":"Muller-Spahn","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0040|cit39","unstructured":"Peuskens J Risperidone in the treatment of chronic schizophrenic patients: an international double blind parallel group comparative study versus haloperidol Clinical Research Report (RIS-INT-2) 1992 (unpublished data from Janssen)"},{"key":"10.1002\/14651858.CD000440-BIB0039|cit40","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind comparative study versus haloperidol","volume":"166","author":"Peuskens","year":"1995","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0041|cit41","unstructured":"Gutierrez R Lemmens P Potkin S Sixth World Congress of Biological Psychiatry; 1997 June 22-27th; Nice, France 1997"},{"key":"10.1002\/14651858.CD000440-BIB0042|cit42","unstructured":"Potkin SG Gutierrez R 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22nd; San Diego, California, USA 1997"},{"issue":"1-2","key":"10.1002\/14651858.CD000440-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0920-9964(97)88689-6","article-title":"Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone or haloperidol","volume":"29","author":"Canadian Cognition and Outcome Study Group","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0044|cit44","unstructured":"Jones B Olanzapine versus risperidone and haloperidol in the treatment of schizophrenia American Psychiatric Association Annual Meeting; 1998 May 30 - June 4th; Toronto, Ontario, Canada 1998"},{"key":"10.1002\/14651858.CD000440-BIB0045|cit45","unstructured":"Purdon SE Jones B Labelle A Addington D Tollefson G Canadian Cognition and Outcome Study Group A multicentre comparison of olanzapine, risperidone, and haloperidol on working memory, new learning, and delayed recall of verbal and nonverbal materials in early-phase schizophrenia over a 12-month prospective double-blind clinical trial Abstracts of the VIIth International Congress on Schizophrenia Research; 1999 April 17-21st; Santa Fe, New Mexico, USA 1999"},{"key":"10.1002\/14651858.CD000440-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone or haloperidol","volume":"57","author":"Purdon","year":"2000","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0006-3223(98)00199-1","article-title":"Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia","volume":"45","author":"See","year":"1999","journal-title":"Society of Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000440-BIB0048|cit48","first-page":"129","article-title":"Risperidone vs Haloperidol: Relative liabilities for OCD and depression","volume":"18","author":"Ames","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0049|cit49","first-page":"129","article-title":"Subjective response to risperidone and haloperidol: Preliminary results","volume":"18","author":"Ames","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0050|cit50","unstructured":"Ames D Wirshing WC Marshall BD Green MF McGurk SR Mintz J Marder SR American Psychiatric Association 150th Annual Meeting; 1997; San Diego, USA 1997"},{"issue":"6","key":"10.1002\/14651858.CD000440-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1176\/ajp.154.6.799","article-title":"Does risperidone improve verbal working memory in treatment-resistant schizophrenia?","volume":"154","author":"Green","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0052|cit52","unstructured":"Kee KS Kern RS Marshall BD Green MF American Psychiatric Association Annual Meeting; 1998 May 30 - June 4th; Toronto, Ontario, Canada 1998"},{"key":"10.1002\/14651858.CD000440-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0920-9964(98)00026-7","article-title":"Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings","volume":"31","author":"Kee","year":"1998","journal-title":"Schizphrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Kern RS Green MF Marshall BD Wirshing WC Ames D Marder SR McGurk S Mintz J Risperidone vs haloperidol on reaction time and fine motor speed 6th International Congress on schizophrenia research;1997; Colorado Springs, Colorado, USA 1997","DOI":"10.1016\/S0920-9964(97)82615-1"},{"key":"10.1002\/14651858.CD000440-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0006-3223(98)00088-2","article-title":"Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenic patients","volume":"44","author":"Kern","year":"1998","journal-title":"Society of Biological Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000440-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oxfordjournals.schbul.a033375","article-title":"Risperidone versus haloperidol on secondary memory: Can newer medications aid learning?","volume":"25","author":"Kern","year":"1999","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD000440-BIB0057|cit57","unstructured":"McGurk SR Green MF Wirshing WC Donna A Marder BD Marder SR Koehn H The effects of risperidone versus haloperidol on frontal lobe functioning in treatment-resistant schizophrenia American Psychiatric Association 150th Annual Meeting;1997; San Diego, USA 1997"},{"issue":"9","key":"10.1002\/14651858.CD000440-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0059|cit59","unstructured":"Wirshing WC Ames D Bray MP Marshall BD Green MF Marder SR Risperidone versus haloperidol in treatment refractory schizophrenia: preliminary results 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25th; Miami, Florida, USA 1995"},{"issue":"3","key":"10.1002\/14651858.CD000440-BIB0060|cit60","first-page":"633","article-title":"Risperidone versus Haloperidol in treatment-refractory schizophrenia: preliminary results","volume":"31","author":"Wirshing","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000440-BIB0061|cit61","unstructured":"Wirshing WC Ames D Marder SR Marshall BD Green MF McGurk S Risperidone in treatment resistant schizophrenia 8th Biennial Winter Workshop on Schizophrenia, 1996 February ; Crans Montana, Switzerland 1996"},{"key":"10.1002\/14651858.CD000440-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/0920-9964(96)85436-3","article-title":"Risperidone versus haloperidol in treatment resistant schizophrenia: preliminary results","author":"Wirshing","year":"1996","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0063|cit63","unstructured":"Wirshing WC Green MF Ames D Marshall BD McGurk SR Mintz J Marder SR Sixth World Congress of Biological Psychiatry; 1997 June 22-27th; Nice, France 1997"},{"key":"10.1002\/14651858.CD000440-BIB0064|cit64","first-page":"1145","article-title":"New antipsychotic agent, risperidone, introduced","volume":"51","author":"Anonymous","year":"1994","journal-title":"American Journal of Hospital Pharmacy"},{"key":"10.1002\/14651858.CD000440-BIB0065|cit65","unstructured":"Axelson R Lindstrom E Dyskinesia in psychotic patients Xth World Congress of Psychiatry; 1996 August 23rd - 28th; Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD000440-BIB0066|cit66","unstructured":"Barak Y Shamir E Weizman R Abstracts of XXIInd CINP Congress; 2000 July 9-13th; Brussels, Belgium 2000"},{"key":"10.1002\/14651858.CD000440-BIB0067|cit67","unstructured":"Berman I Allan ER Pappas D Sison CE Merson A The cognitive effect of risperidone in elderly schizophrenic patients. A pilot double-blind comparison study with haloperidol American Psychiatric Association 150th Annual Meeting; 1997; San Diego, USA 1997"},{"issue":"3","key":"10.1002\/14651858.CD000440-BIB0068|cit68","first-page":"552","article-title":"Effect of risperidone on cognitive performance in elderly schizophrenic patients: a double-blind comparison study with haloperidol","volume":"31","author":"Berman","year":"1995","journal-title":"Psychological Bulletin"},{"key":"10.1002\/14651858.CD000440-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Bilder RM Goldman RS Volavka J Czobor P Hoptman M Sheitman B Lindenmayer JP Citrome L McEvoy J Kunz M Chakos M Cooper TB Lieberman JA Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol on treatment-resistant patients with schizophrenia and schizoaffective disorder International Congress on Schizophrenia Research; 2001 April 28 - May 2nd; Whistler, British Columbia, USA 2001","DOI":"10.1016\/S0924-977X(01)80300-X"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD000440-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0924-977X(96)00012-0","article-title":"Treatment-resistant schizophrenia - clinical experience with new antipsychotics","volume":"6","author":"Bondolfi","year":"1996","journal-title":"European Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0071|cit71","doi-asserted-by":"crossref","unstructured":"Bondolfi G Baumann P Patris M May J Billeter U Dufour H A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia 8th European College of Neuropsychopharmacology Congress; 1995 September 30th - October 4th; Venice, Italy 1995","DOI":"10.1016\/0924-977X(95)90593-3"},{"key":"10.1002\/14651858.CD000440-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Brecher M The Risperidone\/Olanzapine Study Group Risperidone versus olanzepine in the treatment of patients with schizophrenia or schizoaffective disorder 11th CINP Congress; 1998 July 12-16th; Glasgow, Scotland 1998","DOI":"10.1016\/S0924-977X(98)80413-6"},{"key":"10.1002\/14651858.CD000440-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004850-199511000-00001","article-title":"Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis","volume":"10","author":"Carman","year":"1995","journal-title":"International Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0074|cit74","unstructured":"Ceskova E Svestka J XIXth Collegium Internationale Neuro-Psychopharmacologicum Congress; 1994 June 27 - July 1; Washington, D.C., USA 1994"},{"issue":"3-4","key":"10.1002\/14651858.CD000440-BIB0075|cit75","first-page":"151","article-title":"Risperidone vs perphenazine - a double blind comparison and prolactin plasma levels","volume":"6","author":"Ceskova","year":"1994","journal-title":"Psychiatrica Danubina"},{"key":"10.1002\/14651858.CD000440-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Cetin M Ebrinc S Agargun MY Basoglu C Yigit S Yilmaz V Secil M Cobanoglu N Can S Determination of the optimal dose of risperidone in patients with schizophrenia 12th Congress of the European College of Neuropsychopharmacology; 1999 September 21-25th; London, UK 1999","DOI":"10.1016\/S0924-977X(99)80247-8"},{"key":"10.1002\/14651858.CD000440-BIB0077|cit77","first-page":"322","article-title":"Quantative electroencephalogram examination of effects of risperidone in schizophrenic patients","volume":"13","author":"Czober","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1176\/ajp.153.3.417","article-title":"Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study","volume":"153","author":"Daniel","year":"1996","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0079|cit79","first-page":"S26","article-title":"A side effect profile of risperidone vs haloperidol in a double blind randomized comparative group","volume":"40","author":"Deshmukh","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0080|cit80","unstructured":"Estrella MH Soria FL Gonzalez CJ Butron MA Torres JA Escareco RR Cost-effectiveness of Clozapine versus risperidone for treatment-resistant schizophrenic patients Xth World Congress of Psychiatry; 1996 August 23rd-28th; Madrid, Spain 1996"},{"key":"10.1002\/14651858.CD000440-BIB0081|cit81","unstructured":"Gallhofer B 8th European College of Neuropsychopharmacology Congress; 1995 September 30th - October 4th; Venice, Italy 1995"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD000440-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1192\/S0007125000295950","article-title":"Thymosthenic agents, a novel approach in the treatment of schizophrenia","volume":"155","author":"Gelders","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0083|cit83","unstructured":"Gureje O Catts S Fraser H Hustig N Keks Y Lambert J McGrath W Miles A Thomas D Grainger S Andersen G Tollefson Australasian Olanzepine Study Group Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders 11th CINP Congress; 1998 July 12-16th; Glasgow, Scotland 1998"},{"key":"10.1002\/14651858.CD000440-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0278-5846(94)90029-9","article-title":"Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial","volume":"18","author":"Heinrich","year":"1994","journal-title":"Progress in Neuropsychopharmacology and Biological Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000440-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"180a","DOI":"10.1097\/00002826-199201001-00095","article-title":"Risperidone, a new antipsychotic with serotonin 5-HT2 and dopamine D2 antagonistic properties","volume":"15","author":"Heylen","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1097\/00004714-199502001-00008","article-title":"Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia","volume":"15","author":"Klieser","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0087|cit87","first-page":"331","article-title":"Risperidone in comparison with various treatments of schizophrenia","volume-title":"Serotonin in Antipsychotic Treatment. Mechanisms and Clinical Practice","author":"Klieser","year":"1996"},{"key":"10.1002\/14651858.CD000440-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0006-3223(95)00500-5","article-title":"Symptoms in neuroleptic-naive, first-episode schizophrenia - response to risperidone","volume":"39","author":"Kopala","year":"1996","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF02245619","article-title":"Relapse following clozapine withdrawal - effect of neuroleptic drugs and cyproheptadine","volume":"124","author":"Meltzer","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0090|cit90","unstructured":"Muller MJ Wetzel H Benkert O Depressive symptoms in acute psychotic disorders: evaluation methods and treatment strategies 11th CINP Congress; 1998 July 12-16th; Glasgow, Scotland 1998"},{"key":"10.1002\/14651858.CD000440-BIB0091|cit91","unstructured":"Murasaki M Miura S 8th ECNP ( European College of Neuropyschopharmacology) Congress; 1995 September 30th - October 4th; Venice, Italy 1995"},{"key":"10.1002\/14651858.CD000440-BIB0092|cit92","first-page":"221","article-title":"Efficacy of a new antipsychotic, risperidone on schizophrenia","volume":"21","author":"Murasaki","year":"1993","journal-title":"Clinical Evaluation"},{"key":"10.1002\/14651858.CD000440-BIB0093|cit93","doi-asserted-by":"crossref","unstructured":"Nagao M Mori K Kobayakawa M Hirayama S Harada Y Kashiwagi K Irisawa T Nagao K Quantitative electoencephalography in schizophrenia: therapeutic effects of haloperidol and risperidone 11th Congress of the European College of Neuropsychopharmacology; 1998 October 31- November 4; Paris, France 1998","DOI":"10.1016\/S0924-977X(98)80343-X"},{"issue":"1-2","key":"10.1002\/14651858.CD000440-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0920-9964(95)95498-X","article-title":"Relationship between creatine phosphokinase, psychotic symptoms and novel antipsychotic drugs","volume":"15","author":"Pathiraja","year":"1995","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000440-BIB0095|cit95","unstructured":"Sikich L Hooper SR Malekpour AH Sheitman BB Lieberman JA A double blind comparison of typical versus atypical antipsychotic agents on selected neurocognitive functions in children and adolescents with psychotic disorders Abstracts of the VIII International Congress on Schizophrenia Research; 2001 April 28-May 2; British Columbia, Canada 2001"},{"key":"10.1002\/14651858.CD000440-BIB0096|cit96","unstructured":"Zhang XY Zhou DF Zhang PY Shen YC Effects of risperidone and haloperidol on paroxetine-stimulated neuroendocrine responses and blood SOD in schizophrenia 11th CINP Congress; 1998 July 12-16th; Glasgow, Scotland 1998"},{"issue":"2","key":"10.1002\/14651858.CD000440-BIB0097|cit97","first-page":"84","article-title":"Effects of risperidone and haloperidol on paroxetine-evoked neuroendocrine responses in schizophrenia","volume":"32","author":"Zhou","year":"1999","journal-title":"Chinese Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0098|cit98","first-page":"118","article-title":"Changes of positive and negative syndromes - a double-blind clinical trial with risperidone versus haloperidol in chronic schizophrenia","volume":"25","author":"Zinner","year":"1992","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0099|cit99","unstructured":"Risperidone treatment of adolescents with schizophrenia. Ongoing study March 1998"},{"key":"10.1002\/14651858.CD000440-BIB0100|cit100","unstructured":"Antipsychotic treatment in late life schizophrenia. Ongoing study July 1997"},{"key":"10.1002\/14651858.CD000440-BIB0101|cit101","unstructured":"Risperidone and clozapine in chronic schizophrenia. Ongoing study"},{"key":"10.1002\/14651858.CD000440-BIB0102|cit102","unstructured":"Ris-int-35 a double blind evaluation of risperidone versus haloperidol on the long-term morbidity of early psychotic patients Ongoing study Nov 1996"},{"key":"10.1002\/14651858.CD000440-BIB0103|cit103","unstructured":"A double-blind evaluation of risperidone versus haloperidol on the long-term morbidity of early psychotic patients. Ongoing study"},{"key":"10.1002\/14651858.CD000440-BIB0104|cit104","unstructured":"Atypical antipsychotic medications - outcomes and costs. Ongoing study"},{"key":"10.1002\/14651858.CD000440-BIB0105|cit105","first-page":"917","article-title":"Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study","volume":"15","author":"Addington","year":"1993","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD000440-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000440-BIB0107|cit107","first-page":"1","article-title":"Negative syndrome in schizophrenia: strategies for long-term management","volume":"40","author":"Andreasen","year":"1985","journal-title":"Advances in Biochemical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000440-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD000440-BIB0110|cit110","first-page":"233","article-title":"Extrapyramidal Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Science"},{"issue":"suppl 3","key":"10.1002\/14651858.CD000440-BIB0111|cit111","first-page":"89","article-title":"Clinical review of risperidone","volume":"38","author":"Chouinard","year":"1993","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/schbul\/17.2.217","article-title":"When symptoms persist: choosing among alternative somatic symptoms for schizophrenia","volume":"17","author":"Christison","year":"1991","journal-title":"Schizophrenia Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD000440-BIB0113|cit113","article-title":"Cochrane Collaboration Handbook","author":"Clarke","year":"2000","journal-title":"The Cochrane Library [database on disk & CD ROM] The Cochrane Collaboration"},{"key":"10.1002\/14651858.CD000440-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1192\/S0007125000071919","article-title":"Positve and negative schizophrenic symptoms and the role of dopamine","volume":"137","author":"Crow","year":"1980","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00002018-199512020-00006","article-title":"A risk benefit assessment of risperidone in schizophrenia","volume":"12","author":"Curtis","year":"1995","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD000440-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2165\/00003495-197714040-00002","article-title":"Antipsycotic drugs: clinical pharmacology and therapeutic use","volume":"14","author":"Davis","year":"1977","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD000440-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0197-2456(92)90022-R","article-title":"Why register clinical trials?","volume":"13","author":"Dickersin","year":"1992","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD000440-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000440-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/bmj.308.6940.1311","article-title":"Risperidone for schizophrenia","volume":"308","author":"Edwards","year":"1994","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000440-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000440-BIB0121|cit121","first-page":"59","article-title":"Pharmocoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia","volume":"10","author":"Guest","year":"1996","journal-title":"British Journal of Medical Economics"},{"key":"10.1002\/14651858.CD000440-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000440-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10401239409149000","article-title":"Risperidone: review of its pharmacology and therapeutic use in schizophrenia","volume":"6","author":"Gupta","year":"1994","journal-title":"Annals of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0124|cit124","volume-title":"Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000440-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199503000-00003","article-title":"A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors","volume":"10","author":"He","year":"1995","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000440-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0140-6736(05)62158-7","article-title":"Pardonable revisions and protocol reviews","volume":"349","author":"Horton","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000440-BIB0127|cit127","first-page":"470","article-title":"Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased","volume":"316","author":"Irwig","year":"1998","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000440-BIB0128|cit128","volume-title":"Risperidal (risperidone) summary of product characteristics","author":"Janssen-Cilag","year":"1996"},{"issue":"2","key":"10.1002\/14651858.CD000440-BIB0129|cit129","article-title":"Haloperidol versus placebo for schizophrenia","author":"Joy","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000440-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1600-0447.1990.tb05309.x","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"358 (suppl)","author":"Kane","year":"1990","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000440-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2165\/00003495-199346040-00002","article-title":"Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential","volume":"46","author":"Kane","year":"1993","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD000440-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD000440-BIB0133|cit133","first-page":"30","article-title":"Risperidone: the search for a better antipsychotic","volume":"31","author":"Keltner","year":"1995","journal-title":"Perspectives in Psychiatric Care"},{"key":"10.1002\/14651858.CD000440-BIB0134|cit134","first-page":"1","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavicia Supplementum"},{"key":"10.1002\/14651858.CD000440-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(94)92696-4","article-title":"Risperidone","volume":"343","author":"Livingston","year":"1994","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD000440-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/schbul\/18.3.515","article-title":"Treatment of the neuroleptic-nonresponsive schizophrenic patient","volume":"18","author":"Meltzer","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD000440-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"s95","DOI":"10.1111\/j.1600-0447.1994.tb05897.x","article-title":"Recent advances in the pharmacotherapy of schizophrenia","volume":"90","author":"Meltzer","year":"1994","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000440-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bmj.315.7109.617","article-title":"Meta-analysis and the meta-epidemiology of clinical research","volume":"315","author":"Naylor","year":"1997","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000440-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000440-BIB0140|cit140","first-page":"96","article-title":"Clinical considerations in the use of risperidone","volume":"38","author":"Remington","year":"1993","journal-title":"Canadian Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extra-pyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"key":"10.1002\/14651858.CD000440-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/070674379604100823","article-title":"The effect of risperidone on cognition in patients with schizophrenia","volume":"41","author":"Stip","year":"1996","journal-title":"Canadian Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000440-BIB0143|cit143","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000284","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Thornley","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 9","key":"10.1002\/14651858.CD000440-BIB0144|cit144","first-page":"13","article-title":"Behavioural toxicity of antipsychotic drugs","volume":"48","author":"Putten","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000440-BIB0145|cit145","article-title":"Haloperidol dose for the acute phase of schizophrenia","volume-title":"The Cochrane Library","author":"Waraich","year":"2002"},{"key":"10.1002\/14651858.CD000440-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/026988119701100116","article-title":"Risperidone in the treatment of schizophrenia: a metanalysis of randomized controlled trials","volume":"11","author":"Song","year":"1997","journal-title":"Journal of Psychopharmacology"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T10:03:23Z","timestamp":1682589803000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD000440"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2003,4,22]]},"references-count":146,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000440","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,22]]}}}